Fulgent Genetics, Inc.FLGTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank28
3Y CAGR-44.9%
5Y CAGR-44.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-44.9%/yr
vs +6.7%/yr prior
5Y CAGR
-44.9%/yr
Consistent
Acceleration
-51.6pp
Decelerating
Percentile
P28
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.24% |
| Q3 2025 | 2.82% |
| Q2 2025 | 8.75% |
| Q1 2025 | 2.33% |
| Q4 2024 | 2.80% |
| Q3 2024 | -12.63% |
| Q2 2024 | 17.95% |
| Q1 2024 | -4.33% |
| Q4 2023 | 19.35% |
| Q3 2023 | 3.32% |
| Q2 2023 | -0.92% |
| Q1 2023 | 14.96% |
| Q4 2022 | 13.35% |
| Q3 2022 | 8.72% |
| Q2 2022 | 15.29% |
| Q1 2022 | -19.76% |
| Q4 2021 | 23.97% |
| Q3 2021 | 13.35% |
| Q2 2021 | -2.03% |
| Q1 2021 | 18.49% |
| Q4 2020 | 44.04% |
| Q3 2020 | 71.82% |
| Q2 2020 | -6.52% |
| Q1 2020 | 10.19% |
| Q4 2019 | 2.92% |
| Q3 2019 | 10.80% |
| Q2 2019 | 10.53% |
| Q1 2019 | -0.14% |
| Q4 2018 | -0.83% |
| Q3 2018 | 18.65% |
| Q2 2018 | -16.87% |
| Q1 2018 | 10.12% |
| Q4 2017 | 17.38% |
| Q3 2017 | 22.61% |
| Q2 2017 | 8.11% |
| Q1 2017 | 4.03% |
| Q4 2016 | -46.29% |
| Q3 2016 | 132.16% |
| Q2 2016 | 16.93% |
| Q1 2016 | -84.63% |